P60 Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis.
Saved in:
| Title: | P60 Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. |
|---|---|
| Authors: | Hauser, S.L.1 (AUTHOR), Hartung, H.P.1 (AUTHOR), Brochet, B.1 (AUTHOR), Montalban, X.1 (AUTHOR), Naismith, R.T.1 (AUTHOR), Wolinsky, J.S.1 (AUTHOR), Manfrini, M.1 (AUTHOR), Garas, M.1 (AUTHOR), Model, F.1 (AUTHOR), Hubeaux, S.1 (AUTHOR), Kappos, L.1 (AUTHOR) |
| Source: | Clinical Neurophysiology. Aug2019, Vol. 130 Issue 8, pe170-e170. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 13882457 |
|---|---|
| DOI: | 10.1016/j.clinph.2019.04.703 |
